Arrowhead Pharmaceuticals (ARWR) Non-Current Assets (2010 - 2026)

Arrowhead Pharmaceuticals' Non-Current Assets history runs 17 years deep, the most recent figure standing at $428.5 million for Q1 2026.

• Quarterly Non-Current Assets fell 2.23% year-over-year to $428.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 billion (down 1.86% YoY) and the FY2025 annual result came in at $434.7 million, down 2.18% from the prior year.
• Non-Current Assets was $428.5 million for Q1 2026 at Arrowhead Pharmaceuticals, roughly flat from $429.8 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $444.3 million in Q3 2024 and bottomed at $285.9 million in Q1 2022.
• A 5-year average of $381.6 million and a median of $413.5 million in 2024 frame the typical range for Non-Current Assets.
• Peak annual rise in Non-Current Assets reached 68.17% in 2022, while the deepest fall reached 11.95% in 2022.
• Arrowhead Pharmaceuticals' Non-Current Assets stood at $316.5 million in 2022, then climbed by 22.72% to $388.4 million in 2023, then increased by 14.1% to $443.2 million in 2024, then fell by 3.02% to $429.8 million in 2025, then retreated by 0.3% to $428.5 million in 2026.
• Business Quant data shows ARWR's Non-Current Assets at $428.5 million in Q1 2026, $429.8 million in Q4 2025, and $434.7 million in Q3 2025.